Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Allergan Bolsters Blockbuster Botox With Topical Toxin Buy

This article was originally published in Scrip

Executive Summary

Allergan PLC will pay $90m up front to acquire the topical botulinum toxin maker Anterios Inc. in a move that may protect and improve the company's position in aesthetic and therapeutic indications in which the blockbuster wrinkle-reducer and migraine-reliever Botox (onabotulinumtoxinA) is approved.

You may also be interested in...



Medical Aesthetics: Sales Rise For Popular Products, But Unmet Needs Remain

Botox was a game-changer, which means challengers to Allergan's blockbuster are on the way. Dermal fillers and devices also have an important role, but dermatologists say innovation is needed to fill treatment gaps. Business development is ongoing to expand companies' product portfolios.

Acne Pipeline Yields Three Disappointments, One Win So Far In 2017

The pipeline of acne therapeutics is packed with possibilities, but of four candidates to report data so far this year, only one was successful – Allergan's and Paratek's sarecycline, which may be a better antibiotic option, but doesn't give dermatologists a much-needed new mechanism of action.

Allergan Adds Accretive Aesthetics Assets In $2.9bn LifeCell Acquisition

Allergan will pay $2.9bn in cash for LifeCell, a division of Acelity, adding its first regenerative medicine portfolio and marking its first commercial-stage deal in more than a year. The company hopes to exploit the surgical products for aesthetic uses beyond breast reconstruction.

Topics

UsernamePublicRestriction

Register

PS078529

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel